OutSee just raised £1.8M in seed funding to boost its AI-driven genomics platform, Nomaly. The round was led by Ahren Innovation Capital, with Kadmos Capital, Empirical Ventures, and Panacea Ventures also pitching in.
Nomaly uses predictive AI to analyze a single genome and predict disease risks ab initio—no pattern-matching or known data needed. This “genomics first” tech digs into molecular biology to find new drug targets, even from small or previously analyzed datasets.
OutSee plans to use the funds to scale its internal target discovery pipeline, focusing initially on CNS, rare, and metabolic diseases. They aim to partner with pharma and biotech firms to push development further. 
Founder Dr Julian Gough said:
“OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected.”
“I would like to thank our investors, whose support in this endeavour will be crucial in allowing us to build out our in-house target identification program and establish new collaborative partnerships, and to our team for their continued hard work and dedication.”
Chair Dr Paul Wallace added:
“I would like to thank our investors and partners for their support, and for their confidence in our mission to drive therapeutic discovery through our pioneering, genetics first predictive genomics approach. This funding will enable us to leverage the full potential of Nomaly to uncover new therapeutic targets and bolster our in-house pipeline. We remain open to additional investment opportunities, and welcome enquiries from interested pharma and biotech industry partners.”
Ahren Innovation Capital’s Dr Joanna Green said:
“Outsee’s genomics first approach goes far beyond existing technologies, enabling therapeutic developers to precisely comb their data in a way that has never before been possible. Nomaly has great potential to unlock a deeper understanding of genomic data, discover new therapeutic targets and drive the development of next-generation treatments for the entire spectrum of human disease. I look forward to seeing OutSee’s continued growth and success, and to working closely with Julian and the team to support them through this journey.”
OutSee has previously pulled in over £500k in Innovate UK grants to advance precision medicine and dementia studies. Watch this space as they ramp up target discovery with AI.
